DRUG · Unmapped registry intervention
SHR-A1811
Find medicine records ·
Find other trials using this name
Clinical trial
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
NCT07528898
Study summary
ClinicalTrials.govNeoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
4 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Pertuzumab
Normalized identity: pertuzumab View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
trastuzumab
Normalized identity: trastuzumab View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Chemotherapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
SHR-A1811DRUG
PertuzumabDRUG · verified · RxNorm: pertuzumab
trastuzumabDRUG · verified · RxNorm: trastuzumab
ChemotherapyDRUG
Sponsors & collaborators
Hebei Medical University Fourth Hospitallead sponsor
Jiangsu Hengrui Pharmaceutical Co., Ltd.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07528898 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.